DETERMINE is a cutting edge UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.
Patient eligibility information
Any adult patient (aged 18 and over) is eligible to join the trial.
Children and teenagers may be suitable for some treatments on the trial. This is dependent on evidence from other clinical trials demonstrating it's safe.
DETERMINE is a tumour agnostic trial. Patients with any type of cancer can be recruited onto the trial regardless of where it started in the body.
The patient must have had a genetic alteration identified within their tumour or circulating tumour DNA. This must be identified prior to joining the trial through the NHS Genomics Medicine Service or an alternative next generation sequencing report.
The patient must fulfil the eligibility criteria for the trial, as well as any criteria within the specific treatment arm to which they enrol to.
Experts from across the UK will need to review the patient's clinical and genomic data. Additional tests will then be required to ensure that it's safe for them to take part.
Informal eligibility enquiries
We welcome informal enquiries to discuss your patient’s eligibility and next steps. By completing this form you consent to a member of the DETERMINE team getting in touch regarding your enquiry. Please do not include any patient identifiers in this form.
By submitting your informal enquiry, you confirm that you have received verbal consent from your patient to discuss their clinical information. By submitting your informal enquiry, you understand that this is an informal enquiry and that this does not mean that your patient is enrolled onto the trial.
Patient's referral
1. Patient referral
Contact a local investigator at an actively recruiting DETERMINE site to discuss your patient and initiate a referral.
2. Formal submission
After seeking consent from the patient to share their data, the local investigator will make a formal submission to the DETERMINE Molecular Tumour Board (MTB).
You'll need to provide any relevant clinical and genomic data.
3. Decision
The MTB will aim to return their decision to the local investigator within 5 working days.
The patient will need to sign an informed consent document for the specific treatment arm in the trial.
Participating sites
Participant site |
Investigator contact |
Adult/Paediatric |
Status |
| Belfast Health and Social Care Trust, Belfast | Professor Vicky Coyle | Adults | RECRUITING |
Participant site |
Investigator contact |
Adult/Paediatric |
Status |
| Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde), Glasgow | Dr Patricia Roxburgh | Adults | RECRUITING |
| Western General Hospital (NHS Lothian), Edinburgh | Dr Stefan Symeonides | Adults | RECRUITING |
| Royal Hospital For Children Glasgow (NHS Greater Glasgow & Clyde), Glasgow | Dr Milind Ronghe | Paediatric | RECRUITING |
Participant site |
Investigator contact |
Adult/Paediatric |
Status |
| Velindre University NHS Trust, Cardiff | Professor Robert Jones | Adults | RECRUITING |